<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bleomycin-induced lung injury</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bleomycin-induced lung injury</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bleomycin-induced lung injury</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Darren Feldman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel A Culver, DO, FCCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy D Gilligan, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">Bleomycin</a> is an antitumor antibiotic that was isolated from a strain of <em>Streptomyces verticillus</em> in 1966 [<a href="#rid1">1</a>]. It has been used successfully to treat a variety of malignancies, predominantly germ cell tumors and Hodgkin lymphoma. The major limitation of bleomycin therapy is the potential for life-threatening lung injury that occurs in up to 10 percent of patients receiving the drug [<a href="#rid2">2-5</a>]. Injury patterns vary and include diffuse alveolar damage, interstitial fibrosis, nonspecific interstitial pneumonia, organizing pneumonia, and eosinophilic pneumonia [<a href="#rid3">3</a>].</p><p>The pathogenesis, risk factors, evaluation, and treatment of bleomycin-induced lung injury will be reviewed here. A general approach to immunocompromised patients with respiratory symptoms and the evaluation of interstitial lung disease in patients receiving chemotherapy are presented elsewhere. Details regarding choice of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy for the treatment of stromal tumors and Hodgkin lymphoma are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1414434288"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The range of clinical presentations of bleomycin-induced lung injury includes symptoms or physical examination findings (eg, dyspnea, cough, chest pain, and crackles on physical examination), the presence of opacities on chest radiographs, or an asymptomatic decline in diffusing capacity for carbon monoxide (DLCO) during <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy. Uncommonly, bleomycin-induced lung injury may be diagnosed several years after bleomycin exposure as chronic fibrotic lung disease or after an exacerbation of fibrotic lung disease (most commonly in the postoperative setting).</p><p>Symptoms of bleomycin-induced lung injury usually develop subacutely (over days to weeks) within one to six months of beginning <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> treatment but may rarely occur more than six months following the administration of the drug [<a href="#rid6">6</a>]. Symptoms and physical signs associated with bleomycin-induced lung injury are nonspecific, with the earliest symptom being dyspnea and the earliest sign being auscultatory crackles  (<a class="graphic graphic_table graphicRef54965" href="/d/graphic/54965.html" rel="external">table 1</a>) [<a href="#rid4">4</a>].</p><p>Less commonly, the symptoms proceed more rapidly or insidiously, which often suggests particular histopathologic patterns:</p><p class="bulletIndent1"><span class="glyph">●</span>Bleomycin-induced eosinophilic pneumonia and diffuse alveolar damage typically present with more rapidly progressive symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An indolent onset of dyspnea on exertion several months after completion of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy is suggestive of the fibrotic form of bleomycin lung toxicity, similar to interstitial pulmonary fibrosis. (See  <a class="medical medical_review" href="/d/html/14870.html" rel="external">"Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The mechanism of bleomycin-induced lung injury is not entirely clear but likely includes components of oxidative damage, relative deficiency of the deactivating enzyme <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> hydrolase, immunologic responses, elaboration of inflammatory cytokines, and scar formation by myofibroblast activity. Despite these multifactorial mechanisms of toxicity, bleomycin reliably induces dose-dependent pulmonary injury, which has led to its longstanding use as an experimental pulmonary injury and fibrosis model.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action and injury</strong> – The antineoplastic effect of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> is unique among anticancer agents and is thought to involve the production of single- and double-strand breaks in deoxyribonucleic acid (DNA; scission) by a complex of bleomycin, ferrous ions, and molecular oxygen [<a href="#rid2">2,7,8</a>]. Bleomycin binds to DNA by intercalation of the bithiazole moiety between base pairs of DNA and by electrostatic interactions of the terminal amines. The reduction of molecular oxygen by ferrous ions chelated by bleomycin leads to hydrogen subtraction from the C3 and C4 carbons of deoxyribose, resulting in cleavage of the C3-C4 bond and liberation of a base with a DNA strand break [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Study of acute pulmonary injury in rodent models suggests that the initial insult is also due to the primary antineoplastic effect, namely oxidative DNA strand scission with resulting chromosomal injury [<a href="#rid4">4,9-13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung susceptibility and</strong> <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a><strong> hydrolase activity</strong> – Bleomycin hydrolase, an enzyme that degrades bleomycin, is highly active in all tissues with the exception of the skin and the lung, where its lower activity may account for organ-specific toxicity [<a href="#rid2">2,7,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of the innate and adaptive immune response</strong> – The chronic fibrotic response to repeated bleomycin-induced injury has been associated with an acquired further loss of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> hydrolase activity [<a href="#rid15">15</a>] and is mediated by an immunologic mechanism. Nude (athymic) mice are resistant to bleomycin-induced lung injury, suggesting that inflammatory processes are important to the pathogenesis of the disease [<a href="#rid16">16</a>]. The recruitment of both tissue-derived and monocyte-derived macrophages to areas of lung injury has been found to play a role in the development and later resolution of the inflammatory process [<a href="#rid17">17-19</a>]. In contrast, severe combined immunodeficiency (SCID) mice are not resistant, suggesting that T lymphocytes may not play a profibrotic role in the murine model of bleomycin-induced fibrosis [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory cytokines</strong> – In animal models, neutralization of the biologic activity of proinflammatory cytokines with neutralizing antibodies (eg, to anti-tumor necrosis factor alpha [TNFa] and anti-transforming growth factor-beta), soluble receptors (eg, recombinant human TNFa receptors), or receptor antagonists (eg, to interleukin-1) results in the amelioration of bleomycin-induced lung fibrosis [<a href="#rid21">21-24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myofibroblast activity</strong> – Myofibroblast-like cells, which express both smooth-muscle and fibroblast cell markers, increase in number by more than 10-fold after bleomycin-induced injury [<a href="#rid25">25</a>]. Many of these cells are likely derived from the bone marrow [<a href="#rid26">26</a>] and are responsible for the vast majority of new collagen synthesis after bleomycin-induced injury in animal models [<a href="#rid24">24</a>]. This new collagen deposition is thought to be structurally responsible for scar formation and lung fibrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short telomere syndromes</strong> – In animal models, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> induces telomere damage in multiple cell types [<a href="#rid27">27</a>]. Treatment with bleomycin in patients with breast colorectal cancer resulted in more accelerated loss of telomere length in individuals with short baseline telomeres [<a href="#rid28">28</a>]. Short telomere length is a key emerging risk factor for pulmonary toxicity in a variety of interstitial lung diseases, but the effect of bleomycin on human lung disease in individuals with short telomeres has not yet been evaluated.</p><p></p><p class="headingAnchor" id="H978113317"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Several factors influence an individual's risk for the development of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> lung toxicity  (<a class="graphic graphic_table graphicRef75966" href="/d/graphic/75966.html" rel="external">table 2</a>) [<a href="#rid3">3,5,29</a>]. At presentation, patient age, renal function, and severity of the underlying malignancy impact the risk for lung injury. Treatment-associated variables include the cumulative dose of bleomycin, concomitant use of other chemotherapeutic agents, neoadjuvant or simultaneous radiation therapy, or post-treatment thoracic surgery. The risks associated with surgery may be higher with exposures to high levels of oxygen.</p><p class="headingAnchor" id="H3348437032"><span class="h2">Age</span><span class="headingEndMark"> — </span>In most series, the risk of bleomycin-induced lung toxicity appears higher in older patients:</p><p class="bulletIndent1"><span class="glyph">●</span>The United Kingdom Royal Marsden NHS Trust reported that among 835 patients treated with bleomycin-containing regimens for germ cell tumors, the rate of pulmonary complications was more than twice as high among those over 40 years of age (hazard ratio = 2.3) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 141 patients with Hodgkin lymphoma who received regimens including <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, the mean age of those with and without bleomycin toxicity was 49 versus 29 years [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Scottish study of 194 patients treated with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> for germ cell tumors reported that the median age of the five patients who died of pulmonary toxicity was 55 years compared with a median age of 33 years among those who did not develop fatal pulmonary toxicity [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity in 739 United States veterans treated with bleomycin for Hodgkin lymphoma was 9.3 percent overall, with odds ratios of 1.7 (50 to 59 years), 3.2 (60 to 69 years), and 6.0 (≥70 years) compared with those aged ≤49 years [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H623350341"><span class="h2">Cumulative exposure</span><span class="headingEndMark"> — </span>The incidence of bleomycin-induced pulmonary fibrosis is largely dependent on cumulative drug dose [<a href="#rid2">2,32-36</a>]. In patients exposed to a total of 270 international units or less (one international unit = 1 mg), high-grade lung toxicity is seen in 0 to 2 percent, while rates among patients receiving doses of 360 international units or more range from 6 to 18 percent [<a href="#rid2">2,32-35</a>]. Cumulative doses &gt;400 international units are associated with higher rates of pulmonary toxicity and are generally avoided [<a href="#rid37">37</a>]. Although high-grade lung injury is rare with cumulative doses under 400 international units, injury can occur at doses less than 50 international units. Rapid intravenous infusion may also increase the risk of toxicity [<a href="#rid38">38,39</a>]. In large part due to this toxicity, most standard bleomycin-containing treatment regimens lead to a cumulative dose of approximately 200 to 300 international units, with more intensive regimens calling for 300 to a maximum of 400 international units. (See  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Treatment options'</a>.)</p><p class="headingAnchor" id="H3275729255"><span class="h2">Kidney dysfunction</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">Bleomycin</a> is primarily eliminated by the kidney in normal individuals (&gt;80 percent) [<a href="#rid40">40</a>], so impaired kidney function increases the cumulative exposure to the drug and is a risk factor for bleomycin toxicity [<a href="#rid5">5,41</a>]. In one cohort of 835 patients treated with bleomycin-containing regimens for germ cell tumors, the rate of pulmonary complications was over three times higher among those with a glomerular filtration rate &lt;80 mL/minute [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2401788530"><span class="h2">Other chemotherapy and radiation therapy</span><span class="headingEndMark"> — </span>In the treatment of germ cell and ovarian sex-cord-stromal tumors, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> is administered in conjunction with other chemotherapy agents, including <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. At least some data suggest that high cumulative doses of cisplatin also contribute to late impairment of pulmonary function and restrictive lung disease in long-term testicular cancer survivors [<a href="#rid42">42</a>], although others have not found such an association [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Late chemotherapy toxicity'</a>.)</p><p>Concomitant administration of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> may also increase the risk of pulmonary toxicity [<a href="#rid44">44</a>].</p><p>In many (but not all [<a href="#rid36">36,45</a>]) reports, thoracic irradiation increases the risk of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> lung toxicity whether it is administered prior to or simultaneously with bleomycin [<a href="#rid46">46-49</a>]. It is uncertain to what extent a longer interval between radiation therapy (RT) and administration of bleomycin eliminates the increased risk of lung injury.</p><p class="headingAnchor" id="H647248008"><span class="h2">Thoracic surgery and high fractions of inspired oxygen</span><span class="headingEndMark"> — </span>Several case reports have described the development of acute respiratory distress syndrome in patients treated with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> who underwent thoracic procedures within several months of bleomycin administration [<a href="#rid50">50-53</a>]. The relative contributions of high concentrations of oxygen, volutrauma/barotrauma, and volume-associated pulmonary edema to the development of acute respiratory distress syndrome (ARDS) in these patients are highly uncertain. Current practice is to minimize both excess supplemental oxygen and fluid administration and practice lung-protective ventilation in patients requiring general anesthesia after bleomycin administration. (See  <a class="medical medical_review" href="/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults", section on 'Lung protective ventilation during anesthesia'</a> and  <a class="medical medical_review" href="/d/html/1622.html" rel="external">"Adverse effects of supplemental oxygen", section on 'Lung parenchymal injury'</a>.) </p><p>Thoracic surgery has been associated with the development of acute exacerbations of idiopathic pulmonary fibrosis as well as the development of ARDS in the general population. Potential mechanisms include oxidative injury from high oxygen levels as well as volu- or barotrauma from intraoperative mechanical ventilation. Several trials and meta-analyses have found decreased risk of ARDS and lung injury using "lung-protective ventilation" during surgery [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/d/html/110885.html" rel="external">"Acute exacerbations of idiopathic pulmonary fibrosis", section on 'Pathophysiology and risk factors'</a> and  <a class="medical medical_review" href="/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults", section on 'Other risk factors'</a> and  <a class="medical medical_review" href="/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults", section on 'Lung protective ventilation during anesthesia'</a>.)</p><p>Data are conflicting about whether exposure to high concentrations of inspired oxygen specifically increases the likelihood of lung toxicity after <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> chemotherapy. Evidence of potential risk has been derived from animal models, in which coexposure to bleomycin and excess oxygen predispose to increased lung damage, likely via increased oxidative injury [<a href="#rid56">56-58</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p>Case series have largely examined fraction of inspired oxygen (FiO<sub>2</sub>) in the context of surgery, and as such, patient outcomes are subject to several confounding factors. Even in this context, evidence that oxygen exposure increases the risk of pulmonary toxicity is largely anecdotal and conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute respiratory failure from ARDS has been reported following general anesthesia in patients previously treated with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid50">50-53</a>]. Following the death of five bleomycin-treated patients from postoperative pulmonary complications at a single institution, a new intraoperative protocol was developed in which oxygen exposure was minimized and intravenous fluid replacement was judiciously administered [<a href="#rid50">50</a>]. With adoption of this protocol, none of the subsequent 12 patients who underwent post-bleomycin surgery for metastatic germ cell tumors developed pneumonitis or died from postoperative pulmonary complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other data from large case series do not demonstrate a consistent deleterious effect of inspired oxygen on <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> lung injury. In a review of 316 patients who had previous bleomycin chemotherapy and underwent a surgical procedure lasting at least one hour, ARDS developed in seven [<a href="#rid59">59</a>]. No difference was noted in the mean or peak FiO<sub>2</sub> between those who developed ARDS and those who did not. Similarly, a review of 77 patients undergoing major surgery following bleomycin-containing chemotherapy failed to demonstrate a correlation between perioperative oxygen restriction and either postoperative pulmonary morbidity or mortality [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H2237962978"><span class="h2">Cigarette smoking</span><span class="headingEndMark"> — </span>Cigarette smoking is reported to be a risk factor for <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> pulmonary toxicity in some [<a href="#rid4">4,43,61,62</a>] but not all studies [<a href="#rid31">31,41,45,63-66</a>]. The discrepancy may be due to other confounding factors such as bleomycin dose, renal function, patient age, use of other chemotherapeutic agents, and thoracic irradiation. In one study of patients previously treated with bleomycin, current or former cigarette smoking was associated with higher risk for development of ARDS following major surgery [<a href="#rid59">59</a>]. (See <a class="local">'Thoracic surgery and high fractions of inspired oxygen'</a> above.)</p><p class="headingAnchor" id="H1024986979"><span class="h2">Colony stimulating factors</span><span class="headingEndMark"> — </span>Concomitant treatment with granulocyte colony-stimulating factor (G-CSF; <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>) during bleomycin-containing chemotherapy was identified as a possible risk factor for the development of bleomycin-induced lung injury in animal studies. However, data in humans are conflicting [<a href="#rid14">14,29,45,67-72</a>]. One reason for the disparate results may be the confounding influence of age. (See <a class="local">'Incidence'</a> below.)</p><p>Regardless, many clinicians avoid routinely using G-CSF during treatment with regimens containing <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, particularly ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, bleomycin, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>). (See  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma"</a>.)</p><p>In germ cell tumors, G-CSF is typically used only in patients who have had prior febrile neutropenia; when necessary, G-CSF administration is scheduled on a different day than the <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> infusion [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Treatment options'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>The potential for bleomycin-related pulmonary toxicity has been appreciated for many decades, but the scope of the problem is not well documented. The available data on incidence come predominantly from patients treated with a bleomycin-containing regimen for a testicular or ovarian germ cell tumor or ovarian sex cord-stromal tumor, or Hodgkin lymphoma.</p><p class="headingAnchor" id="H3695716999"><span class="h2">Germ cell and ovarian sex cord-stromal tumors</span><span class="headingEndMark"> — </span>In trials of regimens used for germ cell and ovarian sex cord-stromal tumors (typically using 90 international units per cycle for three or four cycles)  (<a class="graphic graphic_table graphicRef65516" href="/d/graphic/65516.html" rel="external">table 3</a>), rates of any grade of pulmonary toxicity range from 5 to 16 percent, and rates of fatal pulmonary toxicity have been in the range of 0 to 1 (for three cycles) and 0 to 3 percent (for four cycles), respectively [<a href="#rid32">32-35,73-81</a>]. With few exceptions [<a href="#rid33">33,34,75</a>], most of these reports defined <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> pulmonary toxicity according to symptoms and clinical findings of pneumonitis and respiratory failure and not by systematic assessment for asymptomatic pulmonary toxicity using pulmonary function tests (PFTs). With careful monitoring of pulmonary function and avoidance of a full-dose fourth cycle, the incidence of pulmonary toxicity from BEP (bleomycin, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>) is on the lower end of this range [<a href="#rid43">43</a>]. (See <a class="local">'Surveillance of asymptomatic patients for lung toxicity'</a> below.)</p><p>Patients with primary mediastinal nonseminomatous germ cell tumors (PMNSGCTs) who require postchemotherapy thoracic surgery to remove residual disease may be more susceptible to postoperative respiratory complications related to <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>; however, the data are inconsistent [<a href="#rid82">82-84</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one report, among 221 patients with PMNSGCT who underwent postchemotherapy mediastinal or lung surgery at a single institution, acute respiratory failure or pneumonia developed in 22 of the 166 patients who had received BEP (13 percent) and in none of the 55 who had received <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (VIP) [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, in a smaller single-center report, there was no significant difference in pulmonary complications among patients with PMNSGCT treated with or without <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. In addition, no fatal pulmonary complications were observed [<a href="#rid84">84</a>].</p><p></p><p>We remain comfortable treating PMNSGCTs with BEP (with serial monitoring of PFTs) in patients without other risk factors for <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> pulmonary toxicity. Appropriate intraoperative management of patients previously treated with BEP, including avoidance of excessive oxygen supplementation and appropriate lung-protective ventilation, is recommended. (See <a class="local">'Thoracic surgery and high fractions of inspired oxygen'</a> above and <a class="local">'Supplemental oxygen and future perioperative management'</a> below and  <a class="medical medical_review" href="/d/html/2998.html" rel="external">"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum", section on 'Mediastinal nonseminomatous GCTs'</a>.)</p><p class="headingAnchor" id="H2298950785"><span class="h2">Hodgkin lymphoma</span><span class="headingEndMark"> — </span>Depending on the definition used and the cumulative <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> dose, rates of bleomycin-induced pulmonary toxicity in adults receiving ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, bleomycin [20 international units/m<sup>2</sup> per course], <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>)  (<a class="graphic graphic_table graphicRef68131" href="/d/graphic/68131.html" rel="external">table 4</a>) for Hodgkin lymphoma range from 10 to 53 percent, and rates of fatal pulmonary toxicity are 4 to 5 percent [<a href="#rid29">29,31,63,72,85,86</a>].</p><p>Higher rates of severe toxicity have been noted among elderly patients [<a href="#rid45">45,87,88</a>] (see <a class="local">'Age'</a> above). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one report, researchers analyzed patients 60 years of age or older who were enrolled in trials comparing two courses of ABVD or AVD (Adriamycin [<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>], <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>), each followed by involved field radiation therapy (RT), versus four cycles of ABVD followed by involved field RT [<a href="#rid87">87</a>]. <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">Bleomycin</a> lung toxicity was uncommon in those whose treatment was limited to two cycles of ABVD (two cases per 137 patients), but it developed in 7 of 68 patients (10 percent) who received four courses of ABVD and was fatal in three (4.4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were noted in a series of 147 individuals with Hodgkin lymphoma age 60 years and over who were treated with at least one to eight (median six) courses of ABVD in three French centers [<a href="#rid45">45</a>]. <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">Bleomycin</a> was stopped in 38 percent of patients and dose-reduced in an additional four percent due to toxicity. Grade 3 or 4 pulmonary toxicity  (<a class="graphic graphic_table graphicRef61493" href="/d/graphic/61493.html" rel="external">table 5</a>) occurred in 21 percent of patients and did not correlate with underlying lung disease, tobacco history, age, use of granulocyte colony-stimulating factor (G-CSF), or RT. Of the 15 deaths from acute toxicity, seven were related to pulmonary toxicity (4.8 percent).</p><p></p><p>eBEACOPP (<a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a> in escalated doses) is an alternative bleomycin-containing chemotherapeutic regimen used in younger patients with high-risk Hodgkin lymphoma. Likely because the cumulative bleomycin dose is generally lower and this regimen is reserved for younger patients, it does not seem to be associated with frequent pulmonary toxicity. (See  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma", section on 'BEACOPP chemotherapy'</a>.)</p><p class="headingAnchor" id="H2806420295"><span class="h1">SURVEILLANCE OF ASYMPTOMATIC PATIENTS FOR LUNG TOXICITY</span><span class="headingEndMark"> — </span>Practices vary in terms of surveillance for lung toxicity during <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy. For patients without risk factors for bleomycin toxicity  (<a class="graphic graphic_table graphicRef75966" href="/d/graphic/75966.html" rel="external">table 2</a>), surveillance may be limited to assessment of symptoms and having a low threshold for stopping bleomycin if dyspnea or nonproductive cough develop. Pulmonary function testing and 18-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) can identify early toxicity in certain settings, although supportive data are limited. We use pulmonary function testing but do not routinely perform surveillance imaging for bleomycin toxicity in asymptomatic individuals.</p><p class="headingAnchor" id="H296884409"><span class="h2">Pulmonary function tests (PFTs)</span><span class="headingEndMark"> — </span>Any use of pulmonary function testing for decision making requires careful assessment of the adequacy of the testing according to American Thoracic Society criteria. Serial PFTs should be obtained in the same laboratory. We assess baseline PFTs, typically spirometry and diffusing capacity for carbon monoxide (DLCO), prior to treatment for all patients with planned bleomycin-containing regimens. In addition, we suggest serial testing at intervals during therapy for the following at risk groups [<a href="#rid89">89</a>] (see <a class="local">'Risk factors'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with germ cell tumors receiving three or four cycles of BEP (<a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Hodgkin lymphoma 50 or older receiving ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with regimens involving concomitant use of colony stimulating factors</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with planned concomitant thoracic radiation or surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected short telomere syndrome in the patient or family members</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with imaging findings suggestive of parenchymal lung disease</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with impaired DLCO (DLCO ≤75 percent predicted or z-score &lt;-1.645) on baseline pulmonary function testing</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with renal insufficiency (estimated glomerular filtration rate [eGFR] &lt;60 mL/min)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ongoing tobacco exposure</p><p></p><p>Appropriate interpretation of the DLCO (including adjustments for anemia and reduced inspiratory capacity) are discussed further below. (See <a class="local">'Pulmonary function testing'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline testing</strong> – Pretreatment PFTs serve as a baseline for future comparisons. In patients who can complete a DLCO maneuver (approximately 10-second full inspiration to total lung capacity), a moderate to severe reduction in DLCO (&lt;40 to 60 percent predicted) may indicate increased risk for higher grade toxicity from <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. Some clinical trials have excluded these patients (exact criteria depending on the study) under the rationale that patients with poor baseline DLCO may be more likely to develop symptomatic or life-threatening pulmonary toxicity with even a small degree of bleomycin injury. Prospective data demonstrating the validity of this approach are lacking.</p><p></p><p class="bulletIndent1">Interpretation of baseline testing can be complicated by inability to perform the maneuver due to airway compression or pain from mediastinal masses. While attempted maneuvers under these circumstances should normally be excluded during interpretation, they occasionally are resulted. In the absence of parenchymal lung disease, reported low DLCO under these circumstances should not exclude patients from receiving <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy. High-resolution computed tomography (HRCT) may be helpful to further characterize baseline risk in patients with uninterpretable DLCO.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing and frequency of follow-up PFTs, and threshold for </strong><a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a><strong> discontinuation</strong> – The optimal frequency of testing during bleomycin therapy is not well established, and various guideline recommendations take different approaches [<a href="#rid89">89,90</a>]. For patients with germ cell tumors, we monitor PFTs prior to each new treatment cycle. For older adults (age ≥60 years) with Hodgkin lymphoma receiving a bleomycin-containing regimen such as ABVD, we monitor closely for symptoms of lung toxicity and repeat PFTs every two to four cycles of therapy or at the onset of symptoms. (See  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma", section on 'Older adults'</a>.)</p><p></p><p class="bulletIndent1">Routine DLCO surveillance is somewhat controversial, in part due to the concern that DLCO surveillance for pulmonary toxicity results in many false positive results and subsequent premature and unnecessary discontinuation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. Intertest variability for DLCO ranges from 4 to 8 mL/min, making assessment of test quality vital. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Quality control'</a>.)</p><p></p><p class="bulletIndent1">Evidence is also mixed on the ability to separate DLCO changes leading to toxicity from those that remain clinically insignificant. On the other hand, data reported from the Danish Testicular Cancer database suggest that a systematic approach to assessing spirometry and DLCO before and after therapy results in discontinuation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> in approximately 10 percent of patients, very low rates of both acute and chronic lung disease, and no detectable impact on oncologic outcomes [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">In early clinical trials, decreases in lung volumes and DLCO appeared to precede the development of severe <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> lung damage, and a decline in DLCO appeared to be the earliest and most sensitive indicator of subclinical lung injury [<a href="#rid91">91,92</a>]. Subsequent studies suggested that PFTs, including DLCO, are neither sensitive nor specific for bleomycin lung toxicity, and many questioned the clinical significance of these changes [<a href="#rid4">4,46,93-95</a>]. At least one randomized trial concluded that changes in PFTs during bleomycin therapy were only weakly correlated with increased toxicity, and only at the end of treatment [<a href="#rid96">96</a>].</p><p></p><p class="headingAnchor" id="H4293295229"><span class="h2">Is there a role for imaging?</span><span class="headingEndMark"> — </span>Monitoring of uptake on 18F-FDG-PET scans has been studied as a potential surveillance method for early detection of bleomycin-induced pulmonary injury, but the data are limited and this is not yet a standard approach [<a href="#rid86">86,97-99</a>]. Despite sensitivity for detecting disease [<a href="#rid100">100</a>], HRCT is not used as a surveillance method due to radiation exposure and concern for overdetection of clinically insignificant changes.</p><p>For patients with Hodgkin lymphoma who are receiving a bleomycin-containing combination such as ABVD, interim 18F-FDG-PET computed tomography (PET-CT) is often obtained to restage disease activity for the purpose of tailoring subsequent treatment. The 18F-FDG-PET appearance in <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity is typically low-level, diffuse, bilateral, often subtle uptake in the lower lobes, which can predate abnormalities on HRCT [<a href="#rid101">101</a>]. While the 18F-FDG-PET pattern is not sufficiently specific to make a diagnosis, any 18F-FDG uptake in the lungs is abnormal and requires further evaluation. (See <a class="local">'Imaging'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h1">EVALUATION OF PATIENTS WITH SUSPECTED PULMONARY TOXICITY</span></p><p class="headingAnchor" id="H3039693624"><span class="h2">When to suspect bleomycin toxicity</span><span class="headingEndMark"> — </span>For patients who develop pulmonary symptoms (eg, dyspnea, cough, or chest pain), new hypoxemia, or crackles on pulmonary examination during or within several months of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> treatment, there should be a high level of concern for bleomycin toxicity. (See <a class="local">'Clinical presentation'</a> above.)</p><p>For asymptomatic patients, a substantial decrease in diffusing capacity for carbon monoxide (DLCO; ie, ≥15 percent decrease from baseline), new parenchymal opacities on chest imaging, or diffuse low-level bilateral uptake in the lungs on surveillance 18-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) raise suspicion for developing toxicity and should prompt further evaluation or close interval follow-up. A decrease in DLCO of more than 25 percent from baseline suggests clinically significant <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity and requires evaluation for alternative causes. (See <a class="local">'Diagnosis and differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>For patients with germ cell tumors and suspected <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity, we obtain tumor markers to rule out tumor progression, although pulmonary progression by germ cell tumors during therapy is rare. We also obtain a complete blood count (CBC) because, rarely, eosinophilia may be present with bleomycin toxicity due to an acute hypersensitivity reaction resulting in eosinophilic pneumonia. If the patient has been on an anthracycline, we obtain a brain natriuretic peptide (BNP) or pro-BNP level to rule out heart failure. (See <a class="local">'Diagnosis and differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/d/html/2999.html" rel="external">"Diagnosis and treatment of relapsed and refractory testicular germ cell tumors", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>In patients with suspected <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity, we typically obtain a chest radiograph. If no obvious alternate explanation is identified, we proceed with noncontrast high-resolution computed tomography (HRCT). There is no established role for other imaging modalities.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong> – We generally obtain a chest radiograph to initially evaluate symptoms or signs of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity and to rule out alternative causes. The appearance of bleomycin-induced lung injury on chest radiographs is variable  (<a class="graphic graphic_table graphicRef75991" href="/d/graphic/75991.html" rel="external">table 6</a>). The classic pattern of bleomycin-induced pulmonary fibrosis includes bibasilar subpleural reticular opacification with volume loss and blunting of the costophrenic angles; however, fine nodular densities may also be present. These early findings may evolve to progressive consolidation and honeycombing. For most patients, findings suggestive of bleomycin toxicity should be further evaluated with cross-sectional imaging. (See  <a class="medical medical_review" href="/d/html/6979.html" rel="external">"Evaluation of diffuse lung disease by conventional chest radiography"</a>.)</p><p></p><p class="bulletIndent1">Pneumothorax and/or pneumomediastinum are rare complications of bleomycin-induced pulmonary fibrosis [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-resolution computed tomography (HRCT)</strong> – Chest HRCT is used to identify suspected occult lung injury, to further characterize the pattern, location, and extent of abnormalities noted on a chest radiograph, or to evaluate gas transfer abnormalities noted on pulmonary function tests (PFTs). It should usually be performed without intravenous contrast.</p><p></p><p class="bulletIndent1">Multiple different patterns of disease may be seen in bleomycin-induced lung injury. HRCT patterns associated with toxicity usually reflect the underlying histopathology [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a> and  <a class="medical medical_review" href="/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Airspace consolidation or ground-glass opacities in dependent locations suggest acute infection or diffuse alveolar damage  (<a class="graphic graphic_diagnosticimage graphicRef71931" href="/d/graphic/71931.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse or upper-lobe predominant bilateral ground-glass opacities and/or centrilobular nodules may suggest eosinophilic pneumonia [<a href="#rid103">103</a>]  (<a class="graphic graphic_diagnosticimage graphicRef71567" href="/d/graphic/71567.html" rel="external">image 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ground-glass opacities, increased reticular markings in a subpleural location, and bronchiolectasis may suggest nonspecific interstitial pneumonitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ground-glass opacities or consolidations in an asymmetric bilateral, subpleural, or peribronchial pattern can suggest secondary organizing pneumonia  (<a class="graphic graphic_diagnosticimage graphicRef81785" href="/d/graphic/81785.html" rel="external">image 3</a>). Rare presentations of organizing pneumonia may show one or more nodular densities, which may mimic tumor metastases [<a href="#rid100">100,104</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extensive reticular markings at the lung periphery, traction bronchiectasis, and honeycombing suggest usual interstitial pneumonia  (<a class="graphic graphic_diagnosticimage graphicRef82237" href="/d/graphic/82237.html" rel="external">image 4</a>).</p><p></p><p class="bulletIndent1">It is important not to confuse the new development of bleomycin-induced inflammatory nodules with progressive cancer. In difficult cases, biopsy may be needed. (See <a class="local">'Diagnosis and differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for 18-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)</strong> – As a diagnostic tool in patients with suspected toxicity, 18F-FDG-PET scans are nonspecific and do not differentiate between <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity and infection. 18F-FDG-PET scanning has been evaluated as a surveillance method for bleomycin pulmonary toxicity. Incidental findings consistent with lung toxicity on 18F-FDG-PET should prompt additional work-up [<a href="#rid101">101</a>]. (See <a class="local">'Is there a role for imaging?'</a> above.)</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>We suggest obtaining spirometry, lung volumes, and DLCO in all patients who develop dyspnea, cough, crackles on chest examination, or an abnormal chest radiograph while receiving <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. In patients with bleomycin-induced lung toxicity, pulmonary function testing typically demonstrates a restrictive lung disease pattern, with decreases in forced vital capacity (FVC), total lung capacity (TLC), functional residual capacity (FRC), and DLCO. Testing may also be helpful in identifying other common causes of cough and dyspnea such as exacerbations of asthma and chronic obstructive pulmonary disease (COPD).</p><p>Most patients treated with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> will have a decrease in their DLCO during treatment, and those with significant pulmonary toxicity will also demonstrate a decrease in lung volumes (eg, FVC and TLC). As an example, two randomized trials comparing a <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, plus bleomycin regimen versus cisplatin plus etoposide alone without bleomycin reported a median decline in DLCO of 14 to 20 percent in the bleomycin arms compared with 0 to 2 percent without bleomycin [<a href="#rid34">34,75</a>]. However, only a small percentage of patients exposed to bleomycin develop clinical signs or symptoms of lung toxicity.</p><p>Reductions in DLCO need to be interpreted with caution. When monitoring DLCO, a corrected "predicted value" for DLCO needs to be calculated for patients with anemia as a decrease in hemoglobin leads to a reduction in carbon monoxide uptake (<a class="calc calc_patient" href="/d/html/83750.html" rel="external">calculator 1</a> and <a class="calc calc_patient" href="/d/html/89706.html" rel="external">calculator 2</a>). The correction for anemia is discussed separately. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Anemia'</a>.)</p><p>Additionally, the DLCO can be affected by airflow limitation due to mediastinal masses, so the DLCO should only be considered valid if the inspiratory volume in the DLCO test is at least 85 percent of the vital capacity, as measured on spirometry. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Quality of testing'</a>.)</p><p class="headingAnchor" id="H326177222"><span class="h2">Invasive testing, in select patients</span></p><p class="headingAnchor" id="H19"><span class="h3">Bronchoalveolar lavage</span><span class="headingEndMark"> — </span>The main role for bronchoalveolar lavage (BAL) in assessing possible <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> lung toxicity is to exclude infection or malignancy as causes of radiographic abnormalities. Only some clinical presentations and CT patterns may be suspicious for infectious and malignant etiologies, so not all patients will require this invasive test. Data regarding typical BAL findings in bleomycin lung toxicity are limited. In one report, neutrophilia was most common, although eosinophilia may be seen in BAL samples from patients with hypersensitivity reactions to bleomycin resulting in eosinophilic pneumonia [<a href="#rid3">3,105,106</a>]. Cytologic atypia with hyperchromatic, multinucleated cells, and prominent macronucleoli may also be seen [<a href="#rid106">106</a>]. (See  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates", section on 'Lung sampling'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Lung biopsy</span><span class="headingEndMark"> — </span>Lung biopsy is rarely needed, as discontinuation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> usually leads to respiratory improvement. If the diagnosis is challenging enough that biopsy is contemplated, we recommend discission of options for obtaining tissue, in the context of the relevant differential diagnosis, in a multidisciplinary discussion that includes clinicians, radiologists and pathologists, prior to invasive procedures. When needed, typically because the etiology of symptoms, signs, and/or radiographic abnormalities remains unclear, tissue has usually been obtained via video-assisted thoracoscopic surgery (VATS) or thoracotomy. Because the histologic patterns of bleomycin lung injury are nonspecific, smaller sample sizes, such as those obtained by forceps biopsies or transbronchial lung cryobiopsy (TBLC), may be inadequate for confident diagnosis. There are currently no data on the usefulness of TBLC in the evaluation of suspected bleomycin toxicity. (See  <a class="medical medical_review" href="/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Overview'</a>.)</p><p class="headingAnchor" id="H3875017428"><span class="h4">Pathology</span><span class="headingEndMark"> — </span>Gross lung specimens from subjects with bleomycin-induced lung injury typically demonstrate a subpleural distribution of lung injury and fibrosis [<a href="#rid2">2</a>]. Histopathology is nonspecific, although squamous metaplasia is a characteristic finding [<a href="#rid4">4</a>]. Various patterns of interstitial lung disease have been described, including usual interstitial pneumonia, nonspecific interstitial pneumonia, diffuse alveolar damage, organizing pneumonia, and eosinophilic pneumonia [<a href="#rid103">103</a>]. More than one of these patterns may be present at the same time [<a href="#rid6">6</a>].</p><p>For patients with a pattern of diffuse alveolar damage, histopathologic findings include endothelial and type I epithelial cell necrosis, type II epithelial cell hyperplasia, and hyaline membranes. In some patients, the diffuse alveolar damage will resolve, in others, it will progress to fibroproliferative lesions and excess collagen deposition.</p><p>Bleomycin-induced pulmonary nodules usually have histopathology similar to diffuse alveolar damage, although patterns of granulomatous infiltration, organizing pneumonia, and eosinophilic pneumonia may also occur [<a href="#rid3">3,103,107</a>]. (See  <a class="medical medical_review" href="/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a> and  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p>Hypersensitivity reactions can demonstrate eosinophilic pneumonia with focal consolidation [<a href="#rid106">106,108,109</a>]. Focal areas of organizing pneumonia and dysplastic type II epithelial cells can also be seen.</p><p class="headingAnchor" id="H21"><span class="h1">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of bleomycin-induced pulmonary toxicity is usually made based on compatible clinical findings (symptoms, signs, pulmonary function test [PFT] abnormalities, and imaging findings) during treatment with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> and the exclusion of infection and pulmonary involvement from the underlying malignancy. After exclusion of other etiologies, we use either pulmonary symptoms with imaging abnormalities or a diffusing capacity for carbon monoxide (DLCO) decrease of at least 25 percent as an indication for treatment, although we recognize that other expert bodies use different cutoffs. (See <a class="local">'Treatment'</a> below.)</p><p>The differential diagnosis of bleomycin-induced lung injury includes lung infection, cardiogenic pulmonary edema, radiation-induced pulmonary fibrosis, metastatic disease, and an adverse reaction to other medications. (See  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H599304681"><span class="h2">Permanent discontinuation of bleomycin</span><span class="headingEndMark"> — </span>The key step in the management of bleomycin-induced pulmonary toxicity is immediate and permanent discontinuation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. Bleomycin should be discontinued in all patients with documented or strongly suspected bleomycin-induced lung injury, including a significant asymptomatic decline in diffusing capacity for carbon monoxide (DLCO). There is no widespread consensus as to the threshold of decline in DLCO that should prompt discontinuation of bleomycin, but we use a 25 percent decrease in DLCO (adjusted for hemoglobin) from the pretreatment value.</p><p>Many experts disagree about the appropriate threshold for discontinuation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy, with the majority suggesting that a threshold drop in DLCO of 15 to 35 percent warrants treatment discontinuation [<a href="#rid43">43,63,79,110-113</a>]. One reason for this disagreement is the concern that routine DLCO surveillance for pulmonary toxicity results in many false positive results, which may lead to the premature and unnecessary discontinuation of bleomycin. However, the reassuring results from the Danish Testicular Cancer database suggest that the 25 percent threshold provides noninferior cancer control accompanied by good long-term pulmonary outcomes [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In this case series, 565 consecutive patients treated with BEP (<a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>) for a germ cell tumor underwent systematic and close monitoring of pulmonary function tests (PFTs) before, during, and for five years after treatment. The maximum cumulative dose of bleomycin was limited for most patients to 150 international units/m<sup>2</sup> (300 international units) by using one-third of the standard dose in the fourth cycle. This is admittedly not currently standard practice for patients with intermediate- and poor-risk germ cell tumors. (See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Intermediate- and poor-risk advanced disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During treatment, 9 percent of patients discontinued <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> due to a decrease in DLCO but subsequently experienced improvement in DLCO into the range of other participants. The mean dose of bleomycin was 142 international units/m<sup>2</sup> among those completing therapy and 100 international units/m<sup>2 </sup>among those in whom bleomycin was stopped early. Persistently reduced lung volumes and DLCO were noted in 4 percent of patients after five years of follow-up. Bleomycin-induced lung toxicity requiring glucocorticoids was noted in two patients, and late (15 years after therapy) appearance of pulmonary fibrosis was reported in three patients.</p><p></p><p>Reinitiation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> is generally not recommended in patients with bleomycin-induced pulmonary toxicity and is contraindicated in patients with pulmonary fibrosis. Successful reinitiation of bleomycin in patients with eosinophilic pneumonia related to bleomycin has been described in case reports [<a href="#rid108">108,114</a>]. However, we suggest not resuming bleomycin in patients who are thought to have eosinophilic pneumonia (as established by high-resolution computed tomography [HRCT] and eosinophilia on bronchoalveolar lavage [BAL] or histopathology) unless there is no effective alternative antineoplastic agent for the patient's disease.</p><p class="headingAnchor" id="H1740138258"><span class="h2">Glucocorticoids, for symptomatic patients with most patterns of injury</span><span class="headingEndMark"> — </span>Although data are limited, we suggest the use of systemic glucocorticoids for most patients with symptomatic respiratory impairment due to suspected <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity after negative work-up for infectious and malignant causes. Exceptions include asymptomatic patients without hypoxemia (for whom discontinuation of bleomycin alone is often sufficient) and those with slow-onset interstitial fibrosis (for whom glucocorticoids are unlikely to be effective and may be harmful). (See <a class="local">'Avoidance of glucocorticoids, in patients with late-onset interstitial fibrosis'</a> below.)</p><p>Because spontaneous resolution is common in patients who have more mild asymptomatic changes in DLCO [<a href="#rid34">34,75,100</a>], we use cessation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> alone and watch for worsening of symptoms and/or DLCO (adjusted for hemoglobin) before initiating glucocorticoids in asymptomatic patients without hypoxemia.</p><p>The optimal dosing and duration of glucocorticoid therapy for symptomatic bleomycin-induced lung injury are not known. Based on clinical experience and data from case series, we typically initiate treatment with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at 0.75 to 1 mg/kg (using ideal body weight [IBW]) per day up to 100 mg per day [<a href="#rid115">115</a>]. After initial therapeutic response, prednisone is generally maintained at 0.5 to 1 mg/kg IBW (approximately 30 to 60 mg per day) for four to six weeks before tapering over three to six months. Prophylaxis for pneumocystis pneumonia should be used when prednisone dose is ≥20 mg. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p>The response to treatment and subsequent taper of glucocorticoids varies somewhat based on the pattern of pulmonary damage. Although the specific histologic type of lung toxicity (eg, nonspecific interstitial pneumonia, diffuse alveolar damage, organizing pneumonia) is rarely definitively established, decisions regarding glucocorticoids are made based on pace of disease, radiographic appearance, and bronchoscopic findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial pneumonitis and diffuse alveolar damage</strong> – Patients with this pattern of lung injury often respond to glucocorticoids, but the response is variable and not always durable. We typically taper glucocorticoids over three to four months in this group depending on their symptomatic and radiographic response to initial therapy and the clinical impact of glucocorticoid side effects.</p><p></p><p class="bulletIndent1">Case reports and case series have described substantial recovery in patients with subacute or acute bleomycin-induced interstitial pneumonitis when a significant inflammatory pneumonitis was present (eg, nonspecific interstitial pneumonia or acute interstitial pneumonia [aka, diffuse alveolar damage]) [<a href="#rid2">2,6,115,116</a>]. In a series of 10 patients with bleomycin-induced lung toxicity, the seven patients who were treated with systemic glucocorticoids experienced significant clinical and radiographic improvements, while the three patients who were not treated with glucocorticoids died [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1">Short-term improvement occurs in 50 to 70 percent of glucocorticoid-treated patients, but symptoms may relapse when therapy is tapered [<a href="#rid115">115</a>]. Some patients who respond to glucocorticoid therapy initially may subsequently develop progressive interstitial pulmonary fibrosis that is unresponsive to glucocorticoid therapy. Pulmonary function abnormalities may or may not improve with therapy and may recur after a period of one to five years, even in patients with an initially positive response to glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organizing pneumonia</strong> – Secondary organizing pneumonia is generally responsive to systemic glucocorticoid therapy, although it can occasionally remit spontaneously. Relapses may occur, most frequently after tapering to relatively low doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. We treat organizing pneumonia in the setting of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity like cryptogenic organizing pneumonia, which is discussed separately  (<a class="graphic graphic_algorithm graphicRef140271" href="/d/graphic/140271.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef140213" href="/d/graphic/140213.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity reactions (eosinophilic pneumonia)</strong> – For patients who are diagnosed with drug-induced hypersensitivity based on an acute onset of symptoms, a consistent radiographic appearance, and either BAL eosinophilia or histopathologic confirmation of eosinophilic pneumonia, the response to glucocorticoid therapy is usually excellent as long as <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> is discontinued. In comparison with other forms of bleomycin-induced lung toxicity, there is usually a more rapid response to glucocorticoid treatment, although this is based on anecdotal reports. Tapering of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is usually accomplished over several weeks [<a href="#rid108">108</a>].</p><p></p><p class="headingAnchor" id="H3220297521"><span class="h2">Avoidance of glucocorticoids, in patients with late-onset interstitial fibrosis</span><span class="headingEndMark"> — </span>Some patients who have a later, more indolent onset of interstitial lung disease after <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> therapy may have a clinical presentation similar to that of idiopathic pulmonary fibrosis. The radiographic pattern on HRCT is consistent with usual interstitial pneumonia (eg, increased reticular markings and evidence of honeycombing, but minimal or absent ground-glass opacities). These patients generally do not have glucocorticoid-responsive disease. The decision to initiate systemic glucocorticoids should be made understanding the low likelihood of benefit and the substantial adverse effects of glucocorticoids. In patients for whom systemic glucocorticoids are initiated, lack of response within two to four weeks should prompt discontinuation of therapy to avoid further adverse side effects. Patients with clinically significant fibrotic disease may benefit from antifibrotic therapy, although this has not been well studied in the setting of bleomycin toxicity. (See <a class="local">'Imaging'</a> above and  <a class="medical medical_review" href="/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Usual interstitial pneumonia'</a> and  <a class="medical medical_review" href="/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Medical therapies'</a>.)</p><p class="headingAnchor" id="H3448649854"><span class="h2">Supplemental oxygen and future perioperative management</span><span class="headingEndMark"> — </span>Although the evidence is largely anecdotal and inconsistent, exposure to high inspired oxygen concentrations in the setting of surgery may increase the risk for pulmonary toxicity even several years out from <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> administration. This may be due to exacerbations of otherwise undiagnosed fibrotic interstitial lung disease. (See <a class="local">'Thoracic surgery and high fractions of inspired oxygen'</a> above.)</p><p>For patients with prior <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> exposure who have hypoxemia, supplemental oxygen should be titrated to an oxygen saturation of 89 to 94 percent. The priority is to maintain adequate oxygen saturation, even if that requires a high fraction of inspired oxygen (FiO<sub>2</sub>). For bleomycin-exposed patients who are undergoing surgery, lung-protective intraoperative strategies are appropriate [<a href="#rid50">50,83,117</a>]. (See  <a class="medical medical_review" href="/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults", section on 'Lung protective ventilation during anesthesia'</a>.)</p><p class="headingAnchor" id="H3208593363"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Even with effective treatment, acute pulmonary toxicity can be fatal in a minority of patients. Long-term respiratory impairment due to <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> pulmonary toxicity is less well-reported, but severe pulmonary dysfunction is uncommon.</p><p>In those with germ cell tumors treated with BEP (<a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>), rates of lethal pulmonary toxicity have been in the range of 0 to 1 (for three courses) and 0 to 3 percent (for four courses), respectively [<a href="#rid32">32-35,73-81</a>]. Patients with Hodgkin lymphoma receiving ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, bleomycin, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>) reportedly die from pulmonary toxicity at a rate of 4 to 5 percent [<a href="#rid29">29,63,72,85,86</a>].</p><p>At five years of follow-up of the Danish Testicular Cancer database, only a minority of BEP-treated patients suffered long-term restrictive disease (4.1 percent) or obstructive lung disease (2.7 percent) [<a href="#rid43">43</a>]. After a median follow-up of 16.1 years, the 15-year cumulative risk for pulmonary disease in treated patients was low and comparable to that of patients with stage I germ cell tumors who received no chemotherapy  (<a class="graphic graphic_table graphicRef107640" href="/d/graphic/107640.html" rel="external">table 7</a>). There were no differences in long-term outcomes among patients who received all of the doses of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> (median 142 international units/m<sup>2</sup>) versus those whose doses were attenuated because of changes in the diffusing capacity for carbon monoxide (DLCO; median dose 100 international units/m<sup>2</sup>).</p><p>In another case series, long-term pulmonary toxicity (unspecified) persisted in 8 percent of patients with germ cell tumors treated with three courses of BEP [<a href="#rid33">33</a>].</p><p>Long-term functional respiratory impairment is reported in approximately 10 to 20 percent of patients after <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> for Hodgkin lymphoma, but this is based on several different measures [<a href="#rid36">36,63,118</a>]. In one case series of 60 patients receiving ABVD, 18 percent had mild pulmonary symptoms at least two years after treatment with ABVD alone, and 30 percent had mild symptoms after ABVD and radiation therapy [<a href="#rid63">63</a>]. In decades-long follow-up of patients receiving primarily bleomycin-containing regimens for Hodgkin lymphoma (with or without chest irradiation), 12 percent of patients showed restrictive spirometry and 21 percent had fibrotic findings on chest radiography [<a href="#rid36">36</a>]. In a final case series with a median follow-up of 57 months, 9 of 67 patients (13 percent) who received bleomycin-containing chemotherapy for Hodgkin lymphoma showed a decrement in DLCO, with only one-third of these also reporting dyspnea [<a href="#rid118">118</a>].</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Most patients with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity are identified based on clinical manifestations, which usually develop between one and six months after treatment initiation. Symptoms and signs include nonproductive cough, dyspnea, pleuritic or substernal chest pain, fever, tachypnea, crackles, and hypoxemia. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older age</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease</p><p class="bulletIndent2"><span class="glyph">•</span>Higher cumulative <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> dose</p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent thoracic radiation</p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a></p><p class="bulletIndent2"><span class="glyph">•</span>Thoracic procedures, particularly including high levels of supplemental oxygen and/or high intraoperative tidal volumes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance of asymptomatic patients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most important step of surveillance for <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity is careful direct questioning and physical examination of the patient to identify symptoms and signs of toxicity that are not initially evident. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We assess baseline spirometry and diffusing capacity for carbon monoxide (DLCO) prior to treatment for all patients with planned bleomycin-containing regimens. For patients with known or suspected parenchymal pulmonary disease or risk factors for <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> pulmonary toxicity  (<a class="graphic graphic_table graphicRef75966" href="/d/graphic/75966.html" rel="external">table 2</a>), we also suggest serial testing at intervals during therapy. (See <a class="local">'Surveillance of asymptomatic patients for lung toxicity'</a> above.)</p><p></p><p class="bulletIndent2">For patients with germ cell tumors, we monitor pulmonary function tests (PFTs) prior to each new treatment cycle. For older adults with Hodgkin lymphoma receiving a bleomycin-containing regimen such as ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>), we assess PFTs after two to four cycles of therapy. (See <a class="local">'Pulmonary function tests (PFTs)'</a> above.)</p><p></p><p class="bulletIndent2">A decrease in DLCO by 15 to 25 percent from baseline should prompt close interval follow-up, while a decrease in DLCO by 25 percent or more requires further evaluation and possible cessation of therapy. (See <a class="local">'When to suspect bleomycin toxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do not use imaging to surveil asymptomatic patients. Suggestive imaging abnormalities on interim scans for disease monitoring may warrant further evaluation. (See <a class="local">'Is there a role for imaging?'</a> above and <a class="local">'When to suspect bleomycin toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of patients with suspected </strong><a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a><strong> toxicity</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with suspected <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity should receive high-resolution computed tomography (HRCT). Typical findings include bibasilar subpleural opacities with volume loss; honeycombing may develop as fibrosis progresses. Radiographic patterns suggestive of eosinophilic or organizing pneumonia may also occur. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest obtaining spirometry, lung volumes, and DLCO in patients with suspected <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> pulmonary toxicity; a restrictive pattern or isolated decrease in DLCO is typically seen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Invasive testing is rarely needed, but bronchoalveolar lavage (BAL) can be used in some patients to exclude infection or malignancy. (See <a class="local">'Bronchoalveolar lavage'</a> above and <a class="local">'Lung biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> - The diagnosis of bleomycin-induced pulmonary toxicity is usually made based on compatible clinical findings during <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> treatment and the exclusion of infectious or malignant causes. (See <a class="local">'Diagnosis and differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">Bleomycin</a><strong> discontinuation</strong> – We recommend permanently discontinuing bleomycin therapy in patients with suspected bleomycin-induced lung injury, including an asymptomatic decrease in the DLCO of 25 percent or more. (See <a class="local">'Permanent discontinuation of bleomycin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of glucocorticoids</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with bleomycin-induced pulmonary toxicity accompanied by symptoms or hypoxemia, we suggest systemic glucocorticoids rather than discontinuation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically initiate therapy using <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.5 to 1 mg/kg ideal body weight (IBW) for four to six weeks, followed by a taper based on radiographic pattern and clinical response. (See <a class="local">'Glucocorticoids, for symptomatic patients with most patterns of injury'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For asymptomatic patients without hypoxemia, we suggest monitoring for development of symptoms or further decline in pulmonary function rather than initiation of glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with chronic pulmonary fibrosis due to <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> toxicity, we suggest avoiding glucocorticoid therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Symptomatic patients with progressive pulmonary fibrosis may benefit from antifibrotic therapy, although this has not been well studied in this population. (See <a class="local">'Avoidance of glucocorticoids, in patients with late-onset interstitial fibrosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Future perioperative management</strong> – Although the evidence is anecdotal, current practice is to minimize excess supplemental oxygen in hypoxemic patients and practice lung-protective ventilation in patients requiring general anesthesia after <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> administration. (See <a class="local">'Supplemental oxygen and future perioperative management'</a> above.)</p><p></p><p class="headingAnchor" id="H17443890"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Philip W Kantoff, MD, Sumanta Pal, MD, and Nicholas Vander Els, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006; 33:98.</a></li><li><a class="nounderline abstract_t">Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11:1.</a></li><li class="breakAll">Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT 2011. p.637.</li><li><a class="nounderline abstract_t">Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617.</a></li><li><a class="nounderline abstract_t">O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14:91.</a></li><li><a class="nounderline abstract_t">Uzel I, Ozguroglu M, Uzel B, et al. Delayed onset bleomycin-induced pneumonitis. Urology 2005; 66:195.</a></li><li><a class="nounderline abstract_t">Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv 1986; 5:81.</a></li><li><a class="nounderline abstract_t">Chandler DB. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med 1990; 11:21.</a></li><li><a class="nounderline abstract_t">Harrison JH Jr, Hoyt DG, Lazo JS. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. Mol Pharmacol 1989; 36:231.</a></li><li><a class="nounderline abstract_t">Hoyt DG, Lazo JS. Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin. Am J Respir Cell Mol Biol 1992; 7:645.</a></li><li><a class="nounderline abstract_t">Fantone JC, Phan SH. Oxygen metabolite detoxifying enzyme levels in bleomycin-induced fibrotic lungs. Free Radic Biol Med 1988; 4:399.</a></li><li><a class="nounderline abstract_t">Martin WJ 2nd, Kachel DL. Bleomycin-induced pulmonary endothelial cell injury: evidence for the role of iron-catalyzed toxic oxygen-derived species. J Lab Clin Med 1987; 110:153.</a></li><li><a class="nounderline abstract_t">Chandler DB, Barton JC, Briggs DD 3rd, et al. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis 1988; 137:85.</a></li><li><a class="nounderline abstract_t">Lazo JS, Merrill WW, Pham ET, et al. Bleomycin hydrolase activity in pulmonary cells. J Pharmacol Exp Ther 1984; 231:583.</a></li><li><a class="nounderline abstract_t">Filderman AE, Genovese LA, Lazo JS. Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol 1988; 37:1111.</a></li><li><a class="nounderline abstract_t">Schrier DJ, Phan SH, McGarry BM. The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis 1983; 127:614.</a></li><li><a class="nounderline abstract_t">Gibbons MA, MacKinnon AC, Ramachandran P, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011; 184:569.</a></li><li><a class="nounderline abstract_t">Cui H, Jiang D, Banerjee S, et al. Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight 2020; 5.</a></li><li><a class="nounderline abstract_t">Tao B, Jin W, Xu J, et al. Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis. J Immunol 2014; 193:2801.</a></li><li><a class="nounderline abstract_t">Helene M, Lake-Bullock V, Zhu J, et al. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999; 65:187.</a></li><li><a class="nounderline abstract_t">Piguet PF, Collart MA, Grau GE, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170:655.</a></li><li><a class="nounderline abstract_t">Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48:959.</a></li><li><a class="nounderline abstract_t">Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993; 5:57.</a></li><li><a class="nounderline abstract_t">Zhang HY, Gharaee-Kermani M, Zhang K, et al. Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Am J Pathol 1996; 148:527.</a></li><li><a class="nounderline abstract_t">Adler KB, Low RB, Leslie KO, et al. Contractile cells in normal and fibrotic lung. Lab Invest 1989; 60:473.</a></li><li><a class="nounderline abstract_t">Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113:243.</a></li><li><a class="nounderline abstract_t">Bolzán AD, Bianchi MS. DNA and chromosome damage induced by bleomycin in mammalian cells: An update. Mutat Res Rev Mutat Res 2018; 775:51.</a></li><li><a class="nounderline abstract_t">Kroupa M, Polivkova Z, Rachakonda S, et al. Bleomycin-induced chromosomal damage and shortening of telomeres in peripheral blood lymphocytes of incident cancer patients. Genes Chromosomes Cancer 2018; 57:61.</a></li><li><a class="nounderline abstract_t">Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614.</a></li><li><a class="nounderline abstract_t">Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998; 78:1061.</a></li><li><a class="nounderline abstract_t">Thomas TS, Luo S, Reagan PM, et al. Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma. J Geriatr Oncol 2020; 11:69.</a></li><li><a class="nounderline abstract_t">Culine S, Kramar A, Théodore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008; 26:421.</a></li><li><a class="nounderline abstract_t">de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19:1629.</a></li><li><a class="nounderline abstract_t">de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15:1837.</a></li><li><a class="nounderline abstract_t">Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13:470.</a></li><li><a class="nounderline abstract_t">Jóna Á, Miltényi Z, Ujj Z, et al. Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity. Expert Opin Drug Saf 2014; 13:1291.</a></li><li><a class="nounderline abstract_t">Blum RH, Carter SK, Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer 1973; 31:903.</a></li><li><a class="nounderline abstract_t">Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99:823.</a></li><li><a class="nounderline abstract_t">Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 1981; 65:419.</a></li><li><a class="nounderline abstract_t">Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer 1996; 32A:550.</a></li><li><a class="nounderline abstract_t">Kawai K, Hinotsu S, Tomobe M, Akaza H. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol 1998; 28:546.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Aass N, Fosså SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27:2779.</a></li><li><a class="nounderline abstract_t">Lauritsen J, Kier MG, Bandak M, et al. Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin. J Clin Oncol 2016; 34:1492.</a></li><li><a class="nounderline abstract_t">Macann A, Bredenfeld H, Müller RP, et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. Int J Radiat Oncol Biol Phys 2008; 70:161.</a></li><li><a class="nounderline abstract_t">Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015; 170:179.</a></li><li><a class="nounderline abstract_t">Villani F, De Maria P, Bonfante V, et al. Late pulmonary toxicity after treatment for Hodgkin's disease. Anticancer Res 1997; 17:4739.</a></li><li><a class="nounderline abstract_t">Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 1976; 235:1117.</a></li><li><a class="nounderline abstract_t">Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 1993; 72:2049.</a></li><li><a class="nounderline abstract_t">Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 1991; 2 Suppl 2:77.</a></li><li><a class="nounderline abstract_t">Goldiner PL, Carlon GC, Cvitkovic E, et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1978; 1:1664.</a></li><li><a class="nounderline abstract_t">Nygaard K, Smith-Erichsen N, Hatlevoll R, Refsum SB. Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer. Cancer 1978; 41:17.</a></li><li><a class="nounderline abstract_t">Gilson AJ, Sahn SA. Reactivation of bleomycin lung toxicity following oxygen administration. A second response to corticosteroids. Chest 1985; 88:304.</a></li><li><a class="nounderline abstract_t">Ingrassia TS 3rd, Ryu JH, Trastek VF, Rosenow EC 3rd. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc 1991; 66:173.</a></li><li><a class="nounderline abstract_t">Guay J, Ochroch EA, Kopp S. Intraoperative use of low volume ventilation to decrease postoperative mortality, mechanical ventilation, lengths of stay and lung injury in adults without acute lung injury. Cochrane Database Syst Rev 2018; 7:CD011151.</a></li><li><a class="nounderline abstract_t">Serpa Neto A, Hemmes SN, Barbas CS, et al. Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis. Lancet Respir Med 2014; 2:1007.</a></li><li><a class="nounderline abstract_t">Tryka AF, Skornik WA, Godleski JJ, Brain JD. Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Morphologic assessment. Am Rev Respir Dis 1982; 126:1074.</a></li><li><a class="nounderline abstract_t">Berend N. Protective effect of hypoxia on bleomycin lung toxicity in the rat. Am Rev Respir Dis 1984; 130:307.</a></li><li><a class="nounderline abstract_t">Tryka AF, Godleski JJ, Brain JD. Differences in effects of immediate and delayed hyperoxia exposure on bleomycin-induced pulmonary injury. Cancer Treat Rep 1984; 68:759.</a></li><li><a class="nounderline abstract_t">Aakre BM, Efem RI, Wilson GA, et al. Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc 2014; 89:181.</a></li><li><a class="nounderline abstract_t">Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160:1347.</a></li><li><a class="nounderline abstract_t">Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003; 63:1565.</a></li><li><a class="nounderline abstract_t">Lower EE, Strohofer S, Baughman RP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci 1988; 295:193.</a></li><li><a class="nounderline abstract_t">Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14:1297.</a></li><li><a class="nounderline abstract_t">Ngeow J, Tan IB, Kanesvaran R, et al. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol 2011; 90:67.</a></li><li><a class="nounderline abstract_t">Ngan HY, Liang RH, Lam WK, Chan TK. Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy. Cancer Chemother Pharmacol 1993; 32:407.</a></li><li><a class="nounderline abstract_t">Haas CD, Coltman CA Jr, Gottlieb JA, et al. Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer 1976; 38:8.</a></li><li><a class="nounderline abstract_t">Fosså SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16:716.</a></li><li><a class="nounderline abstract_t">Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997; 111:657.</a></li><li><a class="nounderline abstract_t">Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137:545.</a></li><li><a class="nounderline abstract_t">Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 8 Suppl 2:S63.</a></li><li><a class="nounderline abstract_t">Younes A, Fayad L, Romaguera J, et al. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006; 42:2976.</a></li><li><a class="nounderline abstract_t">Sun HL, Atenafu EG, Tsang R, et al. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leuk Lymphoma 2017; 58:2607.</a></li><li><a class="nounderline abstract_t">Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16:1287.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25:247.</a></li><li><a class="nounderline abstract_t">de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78:828.</a></li><li><a class="nounderline abstract_t">Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial. J Urol 1997; 157:855.</a></li><li><a class="nounderline abstract_t">Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435.</a></li><li><a class="nounderline abstract_t">Huddart RA, Gabe R, Cafferty FH, et al. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol 2015; 67:534.</a></li><li><a class="nounderline abstract_t">Delanoy N, Pécuchet N, Fabre E, et al. Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis. Int J Gynecol Cancer 2015; 25:1593.</a></li><li><a class="nounderline abstract_t">Necchi A, Miceli R, Oualla K, et al. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. Clin Genitourin Cancer 2017; 15:213.</a></li><li><a class="nounderline abstract_t">Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18:917.</a></li><li><a class="nounderline abstract_t">Ranganath P, Kesler KA, Einhorn LH. Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor. J Clin Oncol 2016; 34:4445.</a></li><li><a class="nounderline abstract_t">Kesler KA, Rieger KM, Hammoud ZT, et al. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 2008; 85:371.</a></li><li><a class="nounderline abstract_t">Caso R, Jones GD, Bains MS, et al. Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. Ann Surg 2021; 274:e1099.</a></li><li><a class="nounderline abstract_t">Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009; 27:5390.</a></li><li><a class="nounderline abstract_t">Falay O, Öztürk E, Bölükbaşı Y, et al. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma. Leuk Lymphoma 2017; 58:1114.</a></li><li><a class="nounderline abstract_t">Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127:2189.</a></li><li><a class="nounderline abstract_t">Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119:692.</a></li><li><a class="nounderline abstract_t">Watson RA, De La Peña H, Tsakok MT, et al. Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer 2018; 119:1044.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Comis RL, Kuppinger MS, Ginsberg SJ, et al. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 1979; 39:5076.</a></li><li><a class="nounderline abstract_t">Pascual RS, Mosher MB, Sikand RS, et al. Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 1973; 108:211.</a></li><li><a class="nounderline abstract_t">McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol 1990; 8:779.</a></li><li><a class="nounderline abstract_t">Ng AK, Li S, Neuberg D, et al. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol 2008; 19:1754.</a></li><li><a class="nounderline abstract_t">Lewis BM, Izbicki R. Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading. JAMA 1980; 243:347.</a></li><li><a class="nounderline abstract_t">Shamash J, Sarker SJ, Huddart R, et al. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol 2017; 28:1333.</a></li><li><a class="nounderline abstract_t">Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica 2007; 92:e120.</a></li><li><a class="nounderline abstract_t">von Rohr L, Klaeser B, Joerger M, et al. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30:320.</a></li><li><a class="nounderline abstract_t">Connerotte T, Lonneux M, de Meeûs Y, et al. Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the early diagnosis of asymptomatic bleomycin-induced pneumonitis. Ann Hematol 2008; 87:943.</a></li><li><a class="nounderline abstract_t">Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin-related lung damage: CT evidence. Radiology 1985; 156:155.</a></li><li><a class="nounderline abstract_t">Dickinson M, Irving L, Hofman M. Early warning signs: FDG-PET to diagnose bleomycin toxicity. Leuk Lymphoma 2017; 58:1016.</a></li><li><a class="nounderline abstract_t">Sikdar T, MacVicar D, Husband JE. Pneumomediastinum complicating bleomycin related lung damage. Br J Radiol 1998; 71:1202.</a></li><li><a class="nounderline abstract_t">Silva CI, Müller NL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR 2006; 27:111.</a></li><li><a class="nounderline abstract_t">Cohen MB, Austin JH, Smith-Vaniz A, et al. Nodular bleomycin toxicity. Am J Clin Pathol 1989; 92:101.</a></li><li><a class="nounderline abstract_t">White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax 1987; 42:551.</a></li><li><a class="nounderline abstract_t">Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004; 25:37.</a></li><li><a class="nounderline abstract_t">Santrach PJ, Askin FB, Wells RJ, et al. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989; 64:806.</a></li><li><a class="nounderline abstract_t">Holoye PY, Luna MA, MacKay B, Bedrossian CW. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978; 88:47.</a></li><li><a class="nounderline abstract_t">Hapani S, Chu D, Wu S. Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report. J Med Case Rep 2010; 4:126.</a></li><li><a class="nounderline abstract_t">Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8:765.</a></li><li><a class="nounderline abstract_t">Jensen JL, Goel R, Venner PM. The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 1990; 65:1291.</a></li><li class="breakAll">Chu E, DeVita VT Jr. Bleomycin. In: Physicians' Cancere Chemotherapy Drug Manual 2016, Chu E, DeVita VT Jr (Eds), Jones and Bartlett Learning, Burlington 2016. p.48.</li><li class="breakAll">Braagalone DL.. Bleomycin. In: Drug Information Handbook for Oncology, 13th, Bragalone DL (Ed), Lexicomp/Wolters Kluwer, Hudson OH 2016. p.212.</li><li><a class="nounderline abstract_t">Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest 1985; 88:103.</a></li><li><a class="nounderline abstract_t">White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 1984; 86:723.</a></li><li><a class="nounderline abstract_t">Maher J, Daly PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993; 48:92.</a></li><li><a class="nounderline abstract_t">Calaway AC, Foster RS, Adra N, et al. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors. J Clin Oncol 2018; 36:2950.</a></li><li><a class="nounderline abstract_t">Avivi I, Hardak E, Shaham B, et al. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. Ann Hematol 2012; 91:215.</a></li></ol></div><div id="topicVersionRevision">Topic 4316 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473648" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary toxicity of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691067" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bleomycin-induced pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691067" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bleomycin-induced pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502668" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bleomycin-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488299" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992893" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Delayed onset bleomycin-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2439200" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Biochemical and cellular determinants of bleomycin cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691068" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Possible mechanisms of bleomycin-induced fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475758" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280451" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2454874" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oxygen metabolite detoxifying enzyme levels in bleomycin-induced fibrotic lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2439623" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bleomycin-induced pulmonary endothelial cell injury: evidence for the role of iron-catalyzed toxic oxygen-derived species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2447814" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6209387" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bleomycin hydrolase activity in pulmonary cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2451525" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6189434" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21680953" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32027623" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25127857" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10088601" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : T cell independence of bleomycin-induced pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475571" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504843" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683505" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8579115" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651799" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Contractile cells in normal and fibrotic lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722616" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bone marrow-derived progenitor cells in pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29555029" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : DNA and chromosome damage induced by bleomycin in mammalian cells: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29052312" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bleomycin-induced chromosomal damage and shortening of telomeres in peripheral blood lymphocytes of incident cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186594" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792151" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31668826" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202419" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11250991" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164193" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7531223" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135756" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4122362" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A clinical review of bleomycin--a new antineoplastic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6197002" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Continuous infusion or bolus injection in cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6165471" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prospective study of the pulmonary toxicity of continuously infused bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8814706" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9793027" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414680" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pulmonary function in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903578" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855012" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25891777" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494599" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Late pulmonary toxicity after treatment for Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/55502" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7689924" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2049323" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/77697" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Factors influencing postoperative morbidity and mortality in patients treated with bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/75052" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2410201" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reactivation of bleomycin lung toxicity following oxygen administration. A second response to corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1704473" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oxygen-exacerbated bleomycin pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985541" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intraoperative use of low volume ventilation to decrease postoperative mortality, mechanical ventilation, lengths of stay and lung injury in adults without acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25466352" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6185024" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Morphologic assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6205617" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Protective effect of hypoxia on bleomycin lung toxicity in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6202406" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Differences in effects of immediate and delayed hyperoxia exposure on bleomycin-induced pulmonary injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485131" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751352" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887263" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term complications of chemotherapy for germ cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2451424" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648387" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676640" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7687934" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/59628" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phase II evaluation of bleomycin. A Southwest oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469362" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118704" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17459049" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284718" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008093" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28504035" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552027" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17235042" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743309" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9072585" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437455" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25001888" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26308607" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692810" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17351252" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621392" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222228" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31977510" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738111" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28185527" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26834240" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22117038" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30356125" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30356125" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/91430" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4124394" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of bleomycin on pulmonary function in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1692088" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18467315" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A prospective study of pulmonary function in Hodgkin's lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6153225" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327896" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024389" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551256" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Increased pulmonary FDG uptake in bleomycin-associated pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443792" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the early diagnosis of asymptomatic bleomycin-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2408293" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bleomycin-related lung damage: CT evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28185528" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Early warning signs: FDG-PET to diagnose bleomycin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10434917" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pneumomediastinum complicating bleomycin related lung damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623365" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2473646" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Nodular bleomycin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2449743" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Bronchoalveolar lavage cell populations in bleomycin lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15062595" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Pathologic characteristics of drug-induced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2472865" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/74226" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Bleomycin hypersensitivity pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20429899" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1692087" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Detecting bleomycin pulmonary toxicity: a continued conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689606" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The effect of corticosteroid administration on bleomycin lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689606" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The effect of corticosteroid administration on bleomycin lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689606" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The effect of corticosteroid administration on bleomycin lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2408822" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6207992" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7679525" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Severe bleomycin lung toxicity: reversal with high dose corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30156983" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21603918" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
